3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Squamous Cell Carcinoma of Head and Neck
287
Head and Neck Neoplasms
256
Carcinoma, Non-Small-Cell Lung
96
Thyroid Neoplasms
93
Melanoma
69
Mouth Neoplasms
67
Oropharyngeal Neoplasms
64
Nasopharyngeal Carcinoma
64
Breast Neoplasms
55
Colorectal Neoplasms
50
Lung Neoplasms
49
Ovarian Neoplasms
45
Neoplasm Metastasis
45
Neoplasms
41
Carcinoma, Squamous Cell
40
Uterine Cervical Neoplasms
39
Carcinoma, Renal Cell
34
Laryngeal Neoplasms
32
Triple Negative Breast Neoplasms
31
Stomach Neoplasms
31
Endometrial Neoplasms
29
Carcinoma
29
Sarcoma
28
Esophageal Neoplasms
28
Pancreatic Neoplasms
27
Salivary Gland Neoplasms
26
Prostatic Neoplasms
25
Thyroid Cancer, Papillary
23
Urinary Bladder Neoplasms
22
Hypopharyngeal Neoplasms
22
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
Head & Neck
×
90 days
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled